COMPANY

Endeavor BioMedicines

HQ: San Diego, CA source · endeavorbiomedicines.com ↗

Keywords: fibrotic diseases respiratory idiopathic pulmonary fibrosis Solid Tumors With PTCH1 Loss-of-function Mutations Progressive Fibrosing Interstitial Lung Disease ENV-101 (taladegib) ENV-101 taladegib

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Raises and deals from press releases

Raise Series C · $132.5M · announced Apr 24, 2024 Company release ↗
Source quote
- Apr 24, 2024 · Company release ↗
  “Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines – Proceeds will support clinical development of lead pipeline candidates: ENV-101 for fibrotic lung diseases including idiopathic pulmonary fibrosis”

Raises announced in these releases: $132.5M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Apr 28, 2026 Trial start Phase 1: A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants source ↗
Nov 15, 2024 Trial start 2: A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) source ↗
Apr 24, 2024 Raise Series C · $132.5M source ↗
May 3, 2023 Trial start Phase 1: A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects source ↗
May 24, 2022 Trial start Phase 2: A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations source ↗
Aug 26, 2021 Trial start Phase 2: A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) source ↗

Upcoming milestones

2026-10 (ESTIMATED) · Phase 1 · A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants · NCT07454291
2026-10 (ESTIMATED) · 2 · A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) · NCT06422884

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT07454291	A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants	Phase 1	Recruiting	Apr 28, 2026	2026-10 (estimated)
NCT05199584	A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations	Phase 2	Completed	May 24, 2022	Feb 20, 2024 (actual)
NCT06422884	A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)	2	Active, not recruiting	Nov 15, 2024	2026-10 (estimated)
NCT04968574	A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)	Phase 2	Completed	Aug 26, 2021	Nov 30, 2023 (actual)
NCT05817240	A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects	Phase 1	Completed	May 3, 2023	Jun 11, 2023 (actual)